For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
Scope of the Report:
This report studies the Factor VIII Deficiency Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Factor VIII Deficiency Treatment market by product type and applications/end industries.
The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
The global Factor VIII Deficiency Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Factor VIII Deficiency Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Bayer HealthCare
- Novo Nordisk
- F. Hoffmann-La Roche
- Biogen Idec
- BioMarin Pharmaceutical
- Sangamo Therapeutics
- Spark Therapeutics
- Swedish Orphan Biovitrum
- Uniqure NV
- Amarna Therapeutics
- Dimension Therapeutics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Hemophilia A Drugs
- Hemophilia A Inhibitors Treatment
- Von Willebrand Disease Treatment
Market Segment by Applications, can be divided into